Research & development
Isofol is developing the drug candidate arfolitixorin for the treatment of advanced colorectal cancer, the third most common form of cancer in the world.
Today, there is a very high need for a more effective baseline treatment of metastatic colorectal cancer (mCRC). The number of people affected increases every year. As of 2020, 1.9 million new cases of colon cancer were diagnosed per year*. Arfolitixorin is currently being evaluated in the ongoing Phase III study AGENT with the aim to contribute to the baseline treatment of colorectal cancer in the future. Isofol currently has no drugs on the market.
* Sources: GLOBOCAN 2020, Cancer Incidence and Mortality Worldwide, GlobalData 2020